BP
AVNR

Ballentine Partners’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Ballentine Partners’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,000
Closed -$138K – 143
2013
Q2 		$138K Buy
+30,000
New +$103K 0.02% 121

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Ballentine Partners's AVNR Position: Q3 2013 in Review

Ballentine Partners sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q3 2013, closing a stake of 30,000 shares — an estimated $138K sold.

Ballentine Partners first reported a position in AVNR in Q2 2013 and held it in 1 quarter. The position peaked at $138K in Q2 2013. 108 funds tracked by Wall St. Rank hold AVNR as of Q3 2013.

  • Ballentine Partners reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q3 2013 after selling out during the quarter.
  • Ballentine Partners sold 30,000 AVANIR PHARMACEUTICALS, INC CL A shares in Q3 2013, an estimated $138K.
  • Ballentine Partners first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 1 quarter.
  • Ballentine Partners's AVANIR PHARMACEUTICALS, INC CL A position peaked at $138K in Q2 2013.
  • 108 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q3 2013.

Based on Ballentine Partners's 13F filing for Q3 2013, filed 29 Oct 2013.